Coagulation factors II, VII, IX, X, Protein C, Protein S
Indications
Coagulation factors II, VII, IX, X, Protein C, Protein S is used for:
COAGULATION FACTOR VIIA RECOMBINANT HUMAN
For treatment of hemorrhagic complications in hemophilia a and b
COAGULATION FACTOR IX (RECOMBINANT)
For treatment of hemophilia (christmas disease)
COAGULATION FACTOR XIII A-SUBUNIT (RECOMBINANT)
For routine prophylaxis of bleeding in patients with congenital factor xiii a-subunit deficiency
For treatment of hemorrhagic complications in hemophilia a and b
COAGULATION FACTOR IX (RECOMBINANT)
For treatment of hemophilia (christmas disease)
COAGULATION FACTOR XIII A-SUBUNIT (RECOMBINANT)
For routine prophylaxis of bleeding in patients with congenital factor xiii a-subunit deficiency
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Coagulation factors II, VII, IX, X, Protein C, Protein S :
Mechanism of Action
COAGULATION FACTOR II
Prothrombin is converted into thrombin which then activated fibrinogen into fibrin
COAGULATION FACTOR VIIA RECOMBINANT HUMAN
Novoseven activates the coagulation or clotting cascade by cleaving factor ix and factor x, which activates them and then leads to activation of thrombin and fibrin
COAGULATION FACTOR IX (RECOMBINANT)
Coagulation factor ix is an important protein in the process of hemostasis and normal blood clotting as it plays a key role within the coagulation cascade. It is located within the blood plasma as a zymogen, an antecedent to enzymatic function, in its inactivated state. Factor ix is dependent on the presence of vitamin k, and is activated to a serine protease by the function of coagulation factor xia. Factor xia cleaves the peptide bond associated with protein activation in factor ix, leaving factor ix with two exposed chains, a light chain and a heavy chain. These two chains are held together by several disulfide bonds that reinforce the structure of factor ix's activated form. After being activated, factor ix forms a complex with calcium ions, membrane phospholipids and coagulation factor viii to activate coagulation factor x. The activation of factor x then performs a similarly integral step in the blood coagulation cascade. The ultimate result of phenotypically normal coagulation factors is the creation of platelets for normal blood clotting
Prothrombin is converted into thrombin which then activated fibrinogen into fibrin
COAGULATION FACTOR VIIA RECOMBINANT HUMAN
Novoseven activates the coagulation or clotting cascade by cleaving factor ix and factor x, which activates them and then leads to activation of thrombin and fibrin
COAGULATION FACTOR IX (RECOMBINANT)
Coagulation factor ix is an important protein in the process of hemostasis and normal blood clotting as it plays a key role within the coagulation cascade. It is located within the blood plasma as a zymogen, an antecedent to enzymatic function, in its inactivated state. Factor ix is dependent on the presence of vitamin k, and is activated to a serine protease by the function of coagulation factor xia. Factor xia cleaves the peptide bond associated with protein activation in factor ix, leaving factor ix with two exposed chains, a light chain and a heavy chain. These two chains are held together by several disulfide bonds that reinforce the structure of factor ix's activated form. After being activated, factor ix forms a complex with calcium ions, membrane phospholipids and coagulation factor viii to activate coagulation factor x. The activation of factor x then performs a similarly integral step in the blood coagulation cascade. The ultimate result of phenotypically normal coagulation factors is the creation of platelets for normal blood clotting